Literature DB >> 18227710

Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma.

Claus Garbe1, Axel Hauschild, Matthias Volkenandt, Dirk Schadendorf, Wilhelm Stolz, Uwe Reinhold, Rolf-Dieter Kortmann, Christoph Kettelhack, Bernhard Frerich, Ulrich Keilholz, Reinhard Dummer, Günther Sebastian, Wolfgang Tilgen, Gerold Schuler, Andreas Mackensen, Roland Kaufmann.   

Abstract

The primary treatment of a melanoma is surgical excision. An excisional biopsy is preferred, and safety margins of 1 cm for tumor thickness up to 2 mm and 2 cm for higher tumor thickness should be applied either at primary excision or in a two-step procedure. When dealing with facial, acral or anogenital melanomas, micrographic control of the surgical margins may be preferable to allow reduced safety margins and conservation of tissue. The sentinel lymph node biopsy should be performed in patients whose primary melanoma is thicker than 1.0 mm and this operation should be performed in centers where both the operative and nuclear medicine teams are experienced. In clinically identified lymph node metastases, radical lymph node dissection is considered standard therapy. If distant metastases involve just one internal organ and operative removal is feasible, then surgery should be seen as therapy of choice. Radiation therapy for the primary treatment of melanoma is indicated only in those cases in which surgery is impossible or not reasonable. In regional lymph nodes, radiation therapy is usually recommended when excision is not complete (R1 resection) or if the nodes are inoperable. In distant metastases, radiation therapy is particularly indicated in bone metastases, brain metastases and soft tissue metastases.

Entities:  

Mesh:

Year:  2008        PMID: 18227710     DOI: 10.1097/CMR.0b013e3282f0c893

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  12 in total

1.  Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection.

Authors:  I M Ising; A Bembenek; R Gutzmer; F Köckerling; K T Moesta
Journal:  Langenbecks Arch Surg       Date:  2011-12-24       Impact factor: 3.445

2.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

3.  Treatment of melanoma.

Authors:  Claus Garbe; Patrick Terheyden; Ulrich Keilholz; Oliver Kölbl; Axel Hauschild
Journal:  Dtsch Arztebl Int       Date:  2008-12-05       Impact factor: 5.594

4.  [Skin cancer in organ transplant patients. Epidemiology and management].

Authors:  U Leiter; C Garbe
Journal:  Hautarzt       Date:  2010-03       Impact factor: 0.751

5.  Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm.

Authors:  Friederike Egberts; A Momkvist; J H Egberts; K C Kaehler; M Weichenthal; A Hauschild
Journal:  Tumour Biol       Date:  2009-12-18

Review 6.  Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I.

Authors:  Luiz Guilherme Martins Castro; Maria Cristina Messina; Walter Loureiro; Ricardo Silvestre Macarenco; João Pedreira Duprat Neto; Thais Helena Bello Di Giacomo; Flávia Vasques Bittencourt; Renato Marchiori Bakos; Sérgio Schrader Serpa; Hamilton Ometto Stolf; Gabriel Gontijo
Journal:  An Bras Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.896

7.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.

Authors:  Bradley N Bidwell; Clare Y Slaney; Nimali P Withana; Sam Forster; Yuan Cao; Sherene Loi; Daniel Andrews; Thomas Mikeska; Niamh E Mangan; Shamith A Samarajiwa; Nicole A de Weerd; Jodee Gould; Pedram Argani; Andreas Möller; Mark J Smyth; Robin L Anderson; Paul J Hertzog; Belinda S Parker
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

8.  Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.

Authors:  B Weide; M Elsässer; P Büttner; A Pflugfelder; U Leiter; T K Eigentler; J Bauer; M Witte; F Meier; C Garbe
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

9.  Functional features of cancer stem cells in melanoma cell lines.

Authors:  Rüdiger M Zimmerer; Philippe Korn; Philippe Demougin; Andreas Kampmann; Horst Kokemüller; André M Eckardt; Nils-Claudius Gellrich; Frank Tavassol
Journal:  Cancer Cell Int       Date:  2013-08-06       Impact factor: 5.722

Review 10.  To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?

Authors:  N J Marciano; T L Merlin; T Bessen; J M Street
Journal:  Int J Clin Pract       Date:  2014-02-18       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.